Table 1 Baseline characteristics of patients in the total, training, and validation cohort
Characteristics | Total cohort (N = 457) | Training cohort, (N = 275) | Validation cohort (N = 182) | P value |
|---|---|---|---|---|
Age | ||||
 ≤ 65 | 205 (44.86%) | 128 (46.55%) | 77 (42.31%) | 0.4262 |
 > 65 | 252 (55.14%) | 147 (53.45%) | 105 (57.69%) | |
Gender | ||||
 Female | 221 (48.36%) | 138 (50.18%) | 83 (45.6%) | 0.3882 |
 Male | 236 (51.64%) | 137 (49.82%) | 99 (54.4%) | |
Stage | ||||
 Stages I–II | 246 (53.83%) | 144 (52.36%) | 102 (56.04%) | 0.3331 |
 Stages III–IV | 196 (42.89%) | 124 (45.09%) | 72 (39.56%) | |
 Not available | 15 (3.28%) | 7 (2.55%) | 8 (4.4%) | |
T | ||||
 T1–2 | 89 (19.47%) | 52 (18.91%) | 37 (20.33%) | 0.6735 |
 T3–4 | 367 (80.31%) | 222 (80.73%) | 145 (79.67%) | |
 Tis | 1 (0.22%) | 1 (0.36%) | 0 (0%) | |
M | ||||
 M0 | 326 (71.33%) | 194 (70.55%) | 132 (72.53%) | 0.8493 |
 M1 | 68 (14.88%) | 43 (15.64%) | 25 (13.74%) | |
 MX/not available | 63 (13.79%) | 38 (13.82%) | 25 (13.74%) | |
N | ||||
 N0 | 261 (57.11%) | 149 (54.18%) | 112 (61.54%) | 0.2282 |
 N1–2 | 195 (42.67%) | 125 (45.45%) | 70 (38.46%) | |
 NX | 1 (0.22%) | 1 (0.36%) | 0 (0%) | |